MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Ligand Pharmaceuticals Incorporated Operating Cash Flow 2011-2026 | LGND
Annual Operating Cash Flow Ligand Pharmaceuticals Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97 M | 49.6 M | 138 M | 78.8 M | 54.6 M | -29.3 M | 194 M | 88.6 M | 60.7 M | 41.7 M | 20.6 M | 20.7 M | 161 K | -1.17 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 194 M | -29.3 M | 58.1 M |
Quarterly Operating Cash Flow Ligand Pharmaceuticals Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -25.4 M | - | - | - | 18.7 M | - | - | - | 33.9 M | - | 84.4 M | 63.9 M | 52 M | - | 51.2 M | 31.1 M | 10.8 M | - | 54 M | 41.3 M | 16.9 M | - | -22 M | -15.8 M | 45.3 M | - | 161 M | 134 M | 60.8 M | - | 57.3 M | 29.6 M | 19.2 M | - | 42 M | 23.5 M | 13.1 M | - | 28.1 M | 17.6 M | 7.58 M | - | 10.3 M | 6.58 M | 2.58 M | - | 8.66 M | 9.02 M | 2.08 M | - | -2.01 M | -1.1 M | -369 K | - | -8.19 M | -7.13 M | 911 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | -25.4 M | 27.1 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.55 | -0.28 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Adagene
ADAG
|
-29.7 M | $ 3.91 | -2.01 % | $ 220 M |  China |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-65.7 M | $ 3.32 | 6.07 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-233 M | $ 4.11 | -2.61 % | $ 105 M | Schweiz |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.79 | 0.04 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 6.39 | -3.62 % | $ 175 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-607 M | $ 706.03 | 0.39 % | $ 25 B |  Niderland |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.34 | -7.48 % | $ 8.04 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 228.06 | -1.28 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
BioCardia
BCDA
|
-9.97 M | $ 1.28 | 0.79 % | $ 27.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-132 M | $ 6.13 | 1.32 % | $ 500 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 3.43 | -4.19 % | $ 7.46 B | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Catalyst Biosciences
CBIO
|
1.01 M | $ 11.1 | -4.15 % | $ 992 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 14.51 | 1.04 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
CNS Pharmaceuticals
CNSP
|
-17.1 M | $ 2.26 | -7.76 % | $ 864 K | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.59 | -1.89 % | $ 16.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.51 | - | $ 385 M | Britain |
 |
BioNTech SE
BNTX
|
890 M | $ 94.86 | 4.77 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |